Table 3 Characteristics of patients and treatment in those who died within 30-days of RT (D30RT) and those who did not (D>30RT)
|  | D30RT (median (IQR) or % (proportion)b) | D>30RT (median (IQR) or % (proportion)b)) | Chi-squared or p-value° |
|---|---|---|---|
Age at diagnosis | 63 (52–70) | 59 (47–67) | 0.002 |
Age at RT | 64 (55–73) | 62 (52–70) | 0.04 |
Gender, % female | 42% (52/125) | 47% (184/393) | 0.35 |
% Hispanic | 5.8% (7/119) | 11% (40/381) | 0.15 |
Survival time (months, diagnosis to RT) | 14 (5–38) | 31 (14–59) | < 0.001 |
KPS at RT consult | 50 (20–70) | 70 (50–80) | < 0.001 |
BMI at RT consult | 22 (IQR 20–25) | 24 (21–27) | 0.001 |
Primary diagnosis breast/prostate | 18% (22/125) | 32% (124/393) | 0.003 |
Treatment site | |||
 Bone | 53% (66/125) | 77% (227/393) | 0.35 |
 Brain | 34% (43/125) | 26% (103/393) | 0.09 |
 Lung | 4% (5/125) | 3% (10/393) |  |
 Othera | 9%(11/125) | 13% (53/393) |  |
Hospitalization within 3 months of consult | 78% (97/125) | 51% (192/375) | < 0.001 |
Metastatic at diagnosis | 50% (62/125) | 50% (191/388) | 0.94 |
Sites of metastases | |||
 Non-bone | 90% (112/125) | 80% (315/392) | 0.08 |
 Brain | 51% (63/124) | 47% (181/387) |  |
 Lung | 62% (78/125) | 53% (206/390) |  |
 Liver | 50% (62/125) | 38% (146/386) |  |
Prescribed fractionsc | 5 (3–10) | 5 (4–10) | 0.14 |
TEACHH Group |  |  | < 0.001 |
 A | 1.6% (2/124) | 9% (30/326) |  |
 B | 74% (92/124) | 80%(260/326) |  |
 C | 24%(30/124) | 11%(36/326) |  |
Chow group |  |  | < 0.001 |
 I | 3% (5/124) | 23% (87/386) |  |
 II | 41% (51/124) | 46% (176/386) |  |
 III | 55% (68/124) | 32% (123/386) |  |
Inpatient consult | 56% (70/125) | 26% (103/393) | < 0.001 |
Hospice involved | 44% (54/122) | 71% (191/270) | < 0.001 |